What is Bacillus licheniformis CECT 5106 used for?

Bacillus licheniformis CECT 5106 is primarily investigated for its ability to support gut health by producing antimicrobial peptides that inhibit pathogenic bacteria like Clostridium perfringens and by potentially reinforcing the intestinal barrier through upregulation of tight junction proteins ZO-1 and occludin. It has been explored in agricultural and emerging probiotic supplement contexts as a gut microbiota modulator. Current human clinical evidence is limited, and its use is considered investigational.

How does Bacillus licheniformis CECT 5106 support gut barrier function?

Studies on related Bacillus licheniformis strains in murine models suggest the bacteria stimulate increased expression of MUC2 (a key mucin protein forming the gut mucus layer), as well as tight junction scaffold proteins ZO-1 and occludin, which physically seal the gaps between intestinal epithelial cells. This dual action may reduce intestinal permeability, sometimes referred to as 'leaky gut,' limiting the translocation of endotoxins and pathogens into systemic circulation. These findings have not yet been confirmed in large-scale human trials for the CECT 5106 strain specifically.

Is Bacillus licheniformis CECT 5106 safe to take daily?

For healthy adults, Bacillus licheniformis species have a well-established safety profile owing to their history in food fermentation and their spore-forming resilience, but CECT 5106 specifically lacks published long-term human safety trials. Immunocompromised individuals face a theoretically elevated risk, as Bacillus species have been linked in rare cases to opportunistic infections in vulnerable patients. Until more robust safety data is published for this strain, daily use should be undertaken under the guidance of a qualified healthcare provider.

What bacteria does Bacillus licheniformis CECT 5106 fight?

Patent-based evidence indicates that Bacillus licheniformis CECT 5106 exhibits antimicrobial activity against Clostridium perfringens, a pathogen responsible for gas gangrene, food poisoning, and necrotic enteritis. The mechanism is believed to involve the secretion of lipopeptide bacteriocins that disrupt bacterial cell membrane integrity. Activity against other common gut pathogens has not been specifically documented in peer-reviewed literature for this particular strain designation.

How does Bacillus licheniformis CECT 5106 differ from other probiotic strains like Lactobacillus?

Unlike Lactobacillus species, Bacillus licheniformis CECT 5106 is a spore-forming bacterium, meaning it forms heat- and acid-resistant endospores that survive harsh conditions including stomach acid, manufacturing processes, and room-temperature storage without refrigeration. Its primary mode of action centers on antimicrobial peptide production and enzymatic activity rather than lactic acid fermentation and direct competitive exclusion typical of Lactobacillus strains. This spore-forming ability may confer greater shelf stability and gastrointestinal survivability, though direct comparative human studies are lacking.

What clinical evidence supports Bacillus licheniformis CECT 5106 effectiveness?

Bacillus licheniformis CECT 5106 is a registered clinical strain with documented in vitro and animal model studies demonstrating antimicrobial activity against pathogens like C. perfringens and the ability to enhance intestinal barrier proteins such as ZO-1 and occludin. However, human clinical trials are limited, with most evidence derived from laboratory and preclinical research rather than large-scale human studies. The strain's efficacy in humans requires further investigation through randomized controlled trials.

Can Bacillus licheniformis CECT 5106 be taken alongside other probiotics?

Bacillus licheniformis CECT 5106 can typically be combined with other probiotic strains, including Lactobacillus species, as evidence suggests it may work synergistically to increase beneficial bacteria populations in the gut microbiota. However, combining multiple probiotic strains may increase the risk of mild digestive adjustment symptoms, so introducing them gradually is advisable. Consult with a healthcare provider before combining multiple probiotic supplements, especially if you have compromised immunity or are taking specific medications.

Who should consider using Bacillus licheniformis CECT 5106 supplements?

Bacillus licheniformis CECT 5106 may be most beneficial for individuals seeking to support gut barrier integrity, maintain healthy microbiota composition, or address occasional digestive discomfort related to dysbiosis. Those with history of C. difficile infection or related pathogenic bacterial overgrowth may find this strain particularly relevant based on its documented antimicrobial properties. Individuals with compromised immune systems, severe GI conditions, or recent antibiotic use should consult a healthcare provider before use to ensure safety and appropriateness.

Bacillus licheniformis CECT 5106

Bacillus licheniformis CECT 5106 is a spore-forming probiotic strain that produces antimicrobial peptides and enzymes targeting pathogenic gut bacteria such as Clostridium perfringens. Its primary mechanism involves modulating gut microbiota composition and reinforcing intestinal barrier integrity through upregulation of tight junction proteins.

Category: Fermented/Probiotic Evidence: 2/10 Tier: Emerging

Bacillus licheniformis CECT 5106 — Hermetica Encyclopedia

Origin & History

Bacillus licheniformis CECT 5106 is a specific strain of gram-positive, spore-forming bacterium isolated for probiotic applications, often used in combination with B. pumilus CECT 5105. The strain is cultured and sporulated for probiotic use, belonging to a class of prokaryotic bacteria that produce bioactive metabolites like cyclic lipopeptides.

Historical & Cultural Context

No historical context or traditional medicine system use is documented for Bacillus licheniformis CECT 5106 or B. licheniformis generally in available sources. The strain appears to be a modern probiotic development without traditional usage history.

Health Benefits

• May support gut barrier function through enhancement of proteins like MUC2, ZO-1, and occludin (based on related strain studies in mice)
• Potential antimicrobial activity against harmful bacteria like C. perfringens (patent evidence only)
• Could modulate gut microbiota composition by increasing beneficial bacteria like Lactobacillus (animal model evidence)
• May support metabolic homeostasis through modulation of aminoacyl-tRNA biosynthesis and purine metabolism pathways (preclinical evidence only)
• Possible anti-inflammatory effects in gut health contexts (based on related strain mouse colitis models)

How It Works

Bacillus licheniformis CECT 5106 produces bacteriocins and lipopeptide antimicrobial compounds that disrupt the cell membranes of competing pathogens such as Clostridium perfringens, reducing their colonization in the gut. The strain stimulates goblet cells to upregulate mucin-2 (MUC2) secretion, thickening the protective mucus layer, while simultaneously enhancing expression of tight junction proteins ZO-1 and occludin to reduce paracellular intestinal permeability. Additionally, it may interact with toll-like receptors (TLR-2 and TLR-4) on enterocytes to modulate downstream NF-κB signaling, dampening pro-inflammatory cytokine production.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically for Bacillus licheniformis CECT 5106 were identified in available sources. Evidence is limited to preclinical studies with related B. licheniformis strains (e.g., ZW3 in mouse DSS-induced colitis models) and co-inoculation mentions with B. pumilus CECT 5105, with no PubMed PMIDs available for human studies of this specific strain.

Clinical Summary

Direct clinical evidence for Bacillus licheniformis CECT 5106 in humans remains limited, with most mechanistic data derived from in vitro cell culture studies and murine models using related Bacillus licheniformis strains. Mouse studies examining homologous strains have demonstrated measurable increases in MUC2, ZO-1, and occludin gene expression, suggesting gut barrier reinforcement, though sample sizes in these studies are typically small (n=10–30 animals per group). Antimicrobial activity against C. perfringens has been documented primarily through patent filings rather than peer-reviewed randomized controlled trials, representing a significant evidence gap. The overall evidence base should be characterized as preliminary, requiring well-designed human RCTs before efficacy claims can be substantiated.

Nutritional Profile

Bacillus licheniformis CECT 5106 is a spore-forming probiotic bacterium, not a conventional food source, so its nutritional profile is defined by its bioactive outputs rather than macronutrient content. As a live microbial supplement (typically delivered at 1×10^8 to 1×10^9 CFU per dose), it contributes negligible calories, fat, carbohydrate, or protein to the diet. Key bioactive compounds and characteristics include: • Extracellular enzymes: produces proteases (subtilisin-like serine proteases, ~0.5–5 U/mL in culture), alpha-amylases, and lipases that may aid nutrient digestion and bioavailability in the gut lumen. • Antimicrobial peptides: produces lichenicidin (a two-component lantibiotic, active at low µg/mL concentrations) and bacitracin (a cyclic polypeptide antibiotic, produced at variable levels depending on strain conditions), which contribute to pathogen inhibition, particularly against Clostridium perfringens and select Gram-positive organisms. • Biosurfactants: produces lichenysin (a lipopeptide surfactant similar to surfactin, typically produced at mg/L levels in fermentation), which may have antimicrobial and biofilm-disrupting properties. • Exopolysaccharides (EPS): produces variable amounts of extracellular polysaccharides that may serve as prebiotic substrates for commensal gut bacteria such as Lactobacillus spp. • Dipicolinic acid (DPA): present within the spore core (~5–15% of spore dry weight), a calcium chelate unique to bacterial endospores; potential antioxidant activity noted in vitro. • B-group vitamins: like many Bacillus species, possesses biosynthetic pathways for riboflavin (B2), folate (B9), and cobalamin (B12), though quantities produced in vivo in the human gut are not well quantified and likely modest. • Spore coat proteins: the spore form provides inherent resistance to gastric acid (pH 1.5–3.0) and bile salts (0.3%), ensuring high survivability and delivery to the lower GI tract — effective bioavailability of the probiotic organism itself is estimated at >85–95% passage through the stomach in spore form. • No significant contribution of dietary fiber, minerals, or fat-soluble vitamins. The primary nutritional relevance is indirect — through enzymatic enhancement of host nutrient absorption (particularly protein and starch digestion), modulation of short-chain fatty acid (SCFA) production by commensal microbiota (butyrate, propionate, acetate), and maintenance of gut epithelial integrity rather than direct macro- or micronutrient provision.

Preparation & Dosage

No clinically studied dosage ranges for Bacillus licheniformis CECT 5106 in humans are documented. Related B. licheniformis strains have been tested at 1-3 g/kg in animal feed studies, but this is not translatable to human dosing. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

B. pumilus CECT 5105, Lactobacillus species, prebiotic fibers, digestive enzymes, L-glutamine

Safety & Interactions

Bacillus licheniformis species are generally regarded as low-risk for healthy adults due to their spore-forming nature and long history in food fermentation, though the specific CECT 5106 strain lacks extensive published human safety data. Individuals who are immunocompromised, post-surgical, or critically ill should exercise caution with any Bacillus-based probiotic, as rare cases of bacteremia have been reported with Bacillus species in vulnerable populations. Potential interactions with antibiotics are plausible, as broad-spectrum antibiotics may reduce strain viability and efficacy; co-administration should be timed at least 2 hours apart. No specific pregnancy or lactation safety data exists for CECT 5106, and use during these periods should be discussed with a healthcare provider prior to supplementation.